GOSS Earnings Date: Nov 4, 2026 (Estimated) — Gossamer Bio, Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is GOSS's next earnings date?
Gossamer Bio, Inc. (GOSS) is expected to report Q3 2026 earnings on Wednesday, November 4, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$3.93 on revenue of $12.2M.
How did GOSS do in its last earnings report?
In its most recent report on Aug 13, 2026 (Q2 2026), Gossamer Bio, Inc. posted EPS of -$0.08 versus the -$9.87 estimate, a beat of 33.3%. Revenue was $9.2M against a $3.6M estimate. The stock's 1-day post-earnings move was -9.4%.
How much does GOSS stock move after earnings?
GOSS beat EPS estimates in 4 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 11.0% (up or down) in the day after earnings.
About Gossamer Bio, Inc.
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-13 | Q2 2026 | -9.87 | -0.08 | +33.33% | $9.2M | ✅ Beat | -9.40% | -7.49% | -21.44% |
| 2026-05-18 | Q1 2026 | -0.17 | -0.20 | -17.65% | $17.0M | ❌ Miss | -43.31% | -38.20% | -50.66% |
| 2026-03-17 | Q4 2025 | -0.20 | -0.21 | -5.00% | $13.8M | ❌ Miss | -7.98% | -26.89% | -7.29% |
| 2025-11-05 | Q3 2025 | -0.19 | -0.21 | -10.53% | $13.3M | ❌ Miss | -2.53% | +13.92% | +40.51% |
| 2025-08-05 | Q2 2025 | -0.18 | -0.17 | +5.56% | $11.5M | ✅ Beat | -8.33% | -10.65% | +16.20% |
| 2025-03-13 | Q4 2024 | -0.17 | -0.15 | +11.76% | $9.4M | ✅ Beat | +11.54% | +3.85% | -36.54% |
| 2024-11-07 | Q3 2024 | -0.15 | -0.14 | +6.67% | $9.5M | ✅ Beat | -0.92% | -13.19% | -13.59% |
| 2024-08-12 | Q2 2024 | 0.23 | 0.22 | -4.35% | $95.8M | ❌ Miss | +3.81% | +17.39% | +11.97% |
Showing last 8 quarters.